Enoxaparin Sodium

[Generic Name]
Enoxaparin Sodium
[Product Standards]
USP/EP/BP/IP
[Certifications]
GMP certifications by the EU, the U.S. FDA, and Brazil, etc.
[Introduction]
Enoxaparin sodium is the sodium salt from degraded heparin. It is one of the most commonly used forms of LMWHs and a standard anticoagulant used in clinical treatment. Enoxaparin sodium was first introduced to the European market in 1987, then to North America in 1993. To date, hundreds of millions of patients in over 100 countries have been treated with enoxaparin sodium. Enoxaparin sodium is a standard anticoagulant therapy with the largest number of indications among all LMWHs.

[Indications]

Prophylaxis of vein thrombosis diseases (prevent intra-vein thrombosis), treatment of deep venous thrombosis, prevention of thrombus formation in the in vitro circulation during hemodialysis, administered with asprin for the treatment of acute unstable angina and non-Q-wave myocardial infarction.